BlackRock, Inc. just filed a "Statement of acquisition of beneficial ownership", which is also known as a 13G. In the filing, it appears as though BlackRock, Inc. claims to own 2498408 shares. This represents 7.6% of Intercept Pharmaceuticals.
Please note that typos are common in SEC filings. Please verify the information reported above before acting on it.
To receive a free e-mail notification whenever Intercept Pharmaceuticals makes a similar move, sign up!
Other recent filings from the company include the following:
Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 2,455 shares - Jan. 13, 2022
Departure of Directors or Certain - Jan. 10, 2022
Statement of changes in beneficial ownership of securities - Jan. 4, 2022
SVP of Intercept Pharmaceuticals just disposed of 2,455 shares - Jan. 4, 2022
Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 1,712 shares - Jan. 4, 2022